Clinical Trials on Chronic B-cell Lymphocytic Leukemia

Total 7894 results

Mayo Clinic
National Cancer Institute (NCI)

Recruiting

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory...

United States
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
Hoffmann-La Roche

Completed

Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Serbia
Kami Maddocks, MD

Active, not recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory/Relapsed Chronic Lymphocytic Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients

Chronic Lymphocytic Leukemia | CLL

Italy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene

Completed

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Chronic Lymphocytic Leukemia | CLL

Austria
Bnai Zion Medical Center
Rambam Health Care Campus; Hadassah Medical Organization; Rabin Medical Center; Assaf-Harofeh Medical Center and other collaborators

Unknown

Heavy Light Chain in Chronic Lymphocytic Leukemia

CLL

Israel
Celgene

Completed

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Leukemia, B-Cell, Chronic

Canada, United States, Germany, Italy, Spain, Sweden, United Kingdom
Ohio State University Comprehensive Cancer Center
Amgen

Completed

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Hematopoietic/Lymphoid Cancer | Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Tampere University Hospital

Completed

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

CLL

Finland
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, United Kingdom
Hoffmann-La Roche

Terminated

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Lymphocytic Leukemia, Chronic

Russian Federation
Hoffmann-La Roche

Terminated

A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

Lymphocytic Leukemia, Chronic

Russian Federation
Hoffmann-La Roche

Completed

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

France
Hoffmann-La Roche

Completed

An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

Lymphocytic Leukemia, Chronic

Spain
Hoffmann-La Roche

Completed

An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Sweden
Pharmacyclics LLC.

Terminated

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia | Leukemia, Lymphocytic, Chronic

United States
BioCryst Pharmaceuticals

Completed

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Gilead Sciences

Terminated

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | B Cell Chronic Lymphocytic Leukemia | B Cells-Tumors | Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)

United States
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL

United States
Genentech, Inc.

Completed

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Lymphocytic Leukemia, Chronic

United States
Hoffmann-La Roche

Completed

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic

Argentina, Venezuela
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic

United Kingdom
Hoffmann-La Roche

Completed

A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Austria
Stanford University

Completed

Transplantation for Patients With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic

United States
AbbVie

Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Region Örebro County

Completed

Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

Vaccine Response | CLL

Sweden
Alexion Pharmaceuticals

Terminated

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Multiple Myeloma | B-cell Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Untreated Chronic Lymphocytic Leukemia

United States
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital; BeiGene USA, Inc.; Roche-Genentech

Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Completed

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

Leukemia | CLL

United States
Januario Castro, M.D.
GlaxoSmithKline

Completed

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) (CRC027)

CLL

United States
Assuta Medical Center

Unknown

Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia

CLL
Titan Pharmaceuticals

Terminated

A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia

Lymphoma, Small Lymphocytic | Leukemia, Lymphocytic, Chronic

United States
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline; University of Virginia

Completed

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia)

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Leukemia

United States
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
Ohio State University Comprehensive Cancer Center

Completed

Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma, Small Lymphocytic | Lymphocytic Leukemia, Chronic

United States
National Cancer Institute (NCI)

Withdrawn

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
AbbVie

Suspended

A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (REVEAL)

Chronic Lymphocytic Leukemia (CLL)

Israel
AstraZeneca
UKCLL Forum

Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom (EPIC)

Chronic Lymphocytic Leukemia, CLL

United Kingdom
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
National University Hospital, Singapore
National University of Singapore

Unknown

Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies

Non-Hodgkin's Lymphoma | B-Cell Chronic Lymphocytic Leukemia

Singapore
Hospital Israelita Albert Einstein
Miltenyi Biotec, Inc.

Not yet recruiting

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia Refractory

Brazil

Clinical Trials on Chronic B-cell Lymphocytic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations